MFDS — authorised 9 May 2023
- Marketing authorisation holder: CHIESI FARMACEUTICI S.P.A
- Status: likely_approved
🇰🇷 Elfabrio in South Korea
MFDS authorised Elfabrio on 9 May 2023
Marketing authorisation
Elfabrio in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in South Korea
Frequently asked questions
Is Elfabrio approved in South Korea?
Yes. MFDS authorised it on 9 May 2023.
Who is the marketing authorisation holder for Elfabrio in South Korea?
CHIESI FARMACEUTICI S.P.A holds the South Korean marketing authorisation.